Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05474430 · ClinicalTrials.gov registry record
Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
A clinical trial of Carrier State and Respiratory Infections, sponsored by Philip Polgreen.
- Recruiting
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT05474430 is a study of Carrier State and Respiratory Infections that is actively recruiting participants, run by Philip Polgreen. The registered enrollment target is 160 participants, below the 1,150-participant average among 3 other Carrier State trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05474430, a study of Carrier State and Respiratory Infections, is actively recruiting participants, sponsored by Philip Polgreen.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19. The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.
Conditions Studied
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05474430
The ClinicalTrials.gov registry entry for NCT05474430 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,150-participant average among 3 other Carrier State trials with a reported enrollment target (86% lower). The listed sponsor is Philip Polgreen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carrier State appearing as the primary indexed condition, and to 0 interventions.
NCT05474430 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05474430 about?
NCT05474430 is a clinical study titled "Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity". A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactiv...
What is the current status of trial NCT05474430?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2021-12-20. Estimated completion is 2026-07.
What conditions does trial NCT05474430 study?
This clinical trial studies the following conditions: Carrier State, Respiratory Infections.
Who is sponsoring clinical trial NCT05474430?
This trial is sponsored by Philip Polgreen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05474430 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carrier State
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.